Literature DB >> 21682621

Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go?

Valsamma Eapen1, George John.   

Abstract

OBJECTIVE: Childhood obesity and its sequelae, including metabolic syndrome, are reaching epidemic proportions worldwide. Young people treated with antipsychotic medication are particularly at risk as they experience significant weight gain as a side effect of second generation antipsychotics (SGAs) with consequent increased risk of type 2 diabetes, cardiovascular morbidity and metabolic syndrome. However, surveillance for these side effects is not carried out nor intervention offered in routine clinical prctice. This paper examines the current state of evidence on this topic and suggests directions for future research and clinical practice.
CONCLUSIONS: Systematic monitoring and preventative programs aimed at weight gain and metabolic side effects should form an integral part of the comprehensive management of adolescents on SGAs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21682621     DOI: 10.3109/10398562.2010.539609

Source DB:  PubMed          Journal:  Australas Psychiatry        ISSN: 1039-8562            Impact factor:   1.369


  8 in total

Review 1.  Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.

Authors:  José María Martínez-Ortega; Silvia Funes-Godoy; Francisco Díaz-Atienza; Luis Gutiérrez-Rojas; Lucía Pérez-Costillas; Manuel Gurpegui
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-03-17       Impact factor: 4.785

Review 2.  The clinical and behavioral cardiometabolic risk of children and young people on mental health inpatient units: A systematic review and meta-analysis.

Authors:  Rebekah Carney; Joseph Firth; Rebecca Pedley; Heather Law; Sophie Parker; Karina Lovell
Journal:  Gen Hosp Psychiatry       Date:  2021-03-15       Impact factor: 3.238

3.  A descriptive study of biological and psychosocial factors associated with body mass index for age, in adolescents attending an outpatient department at Weskoppies Psychiatric Hospital.

Authors:  Kgomotso R Ncube; Nadira Khamker; Deborah van der Westhuizen; Thea Corbett
Journal:  S Afr J Psychiatr       Date:  2017-08-31       Impact factor: 1.550

Review 4.  The effects of antipsychotic medications on microbiome and weight gain in children and adolescents.

Authors:  Tali Bretler; Hagar Weisberg; Omry Koren; Hadar Neuman
Journal:  BMC Med       Date:  2019-06-19       Impact factor: 8.775

Review 5.  The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.

Authors:  Mark R Libowitz; Erika L Nurmi
Journal:  Front Psychiatry       Date:  2021-03-12       Impact factor: 4.157

6.  Metabolic effects of adding Topiramate on Aripiprazole in bipolar patients aged between 6-18 years, a randomized, double-blind, placebo-controlled trial.

Authors:  Soroor Arman; Mostafa Haghshenas
Journal:  J Res Med Sci       Date:  2022-03-17       Impact factor: 1.852

7.  Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer Use of Antipsychotics in Youth (SUAY) Clinical Trial.

Authors:  Robert B Penfold; Ella E Thompson; Robert J Hilt; Nadine Schwartz; Adelaide S Robb; Christoph U Correll; Douglas Newton; Kelly Rogalski; Marian F Earls; Robert A Kowatch; Arne Beck; Bobbi Jo H Yarborough; Stephen Crystal; Benedetto Vitiello; Kelly J Kelleher; Gregory E Simon
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2021-05-04       Impact factor: 8.829

Review 8.  Antipsychotic-associated weight gain: management strategies and impact on treatment adherence.

Authors:  Madhubhashinee Dayabandara; Raveen Hanwella; Suhashini Ratnatunga; Sudarshi Seneviratne; Chathurie Suraweera; Varuni A de Silva
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-22       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.